The current results indicate that CA125 and HE4 are strong indicators, AFP may be helpful, and CEA is a weak biomarker for ovarian tumor/cancer diagnosis, and more samples need to be tested to further validate the results in the future. This evidence concerns the gene WFDC2 and ovarian neoplasm.